Page results
-
A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCLH, UCL and the Francis Crick Institute.
-
This page tells you about having a Non-Tunnelled CVC Line Insertion (Vascath). This page is for those patients who have been referred to Interventional Radiology.
-
This page tells you about having a PICC (Peripherally Inserted Central Catheter) line insertion with the Interventional Radiology team.
-
This booklet tells you about having a Vortex® Port-a-cath Insertion (implantable port) with the Interventional Radiology team.
-
This page tells you about having a PICC (Peripherally Inserted Central Catheter) line insertion with the Vascular Access team.
-
This page is for patients who have been referred by their GP to a gynaecology specialist because their symptoms need further tests.
-
A research team involving UCLH clinicians has found a way to reduce the side effects of treatment for a disorder of the adrenal glands.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
This page is for patients who have been referred on a suspected cancer pathway.
-
At UCLH we run seasonal COVID-19 vaccination clinics from our Hospital Hub within UCH. Vaccinations are available to members of the eligible public as well as UCLH patients.
File results
-
FOI/2024/0440 - Patient reported outcome measures (PROMs) in oncology
-
FOI/2024/0361 - Recording RTT waiting times: Planned patients guidance
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0357 - Multiple myeloma treatments
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details
-
FOI/2024/0371 - Acute myeloid leukaemia treatment
-
FOI/2024/0376 - Advice provided on topical medication for eczema patients